Brief: Aytu Biopharma Announces FDA Clearance Of IND Application For AR101/Enzastaurin In Vascular Ehlers-Danlos Syndrome

Aytu Biopharma

13/12/2021 13:18

Dec 13 (Reuters) - Aytu Biopharma Inc  AYTU.O :
    * AYTU BIOPHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR AR101/ENZASTAURIN IN VASCULAR EHLERS-DANLOS
SYNDROME
    * AYTU BIOPHARMA - PLANS TO INITIATE PREVENT TRIAL IN VEDS
IN
FIRST HALF OF 2022

Source: (https://bit.ly/3s1GlUU)
Further company coverage:  AYTU.O 

 ((Reuters.Briefs@thomsonreuters.com;))